Abstract
Prospective epidemiologic studies have shown that dyslipidemia and hyperglycemia are major risk factors for atherosclerotic cardiovascular diseases. Undesirable metabolic conditions are observed to coexist in patients with metabolic syndrome, which is an important risk factor for cardiovascular disease. To prevent cardiovascular disease, a pleiotropic agent is needed to improve the metabolic disorder in patients with metabolic syndrome. Bile acid binding resins increase the fecal excretion of bile acids. The decrease in bile acids returned to the liver leads to an up-regulation of hepatic low-density lipoprotein (LDL) receptor activity, which decreases LDL cholesterol (LDL-C) in the circulation and increases high-density lipoprotein cholesterol. On the other hand, bile acids can also regulate the transcription of genes involved in LDL-C synthesis and cholesterol homeostasis via nuclear hormone receptors. Consequently, these receptors may represent novel therapeutic targets for dyslipidemia and provide insight into the role of the bile acid pathway in other metabolic processes. This review focuses on the recent findings on bile acid binding resins and cardiovascular disease risk factors. Moreover, known and proposed mechanisms of how bile acid binding resins may improve glucose and energy metabolism are discussed; these effects may help to explain the mechanisms by which bile acid binding resins may reduce cardiovascular disease.
Keywords: Anion-exchange resins, bile acids, pleiotropic effects, insulin resistance, diabetes mellitus, inflammation, metabolic syndrome, obesity
Current Vascular Pharmacology
Title: Beyond Cholesterol Lowering: Pleiotropic Effects of Bile Acid Binding Resins Against Cardiovascular Disease Risk Factors in Patients with Metabolic Syndrome
Volume: 6 Issue: 4
Author(s): Minako Yamaoka-Tojo, Taiki Tojo and Tohru Izumi
Affiliation:
Keywords: Anion-exchange resins, bile acids, pleiotropic effects, insulin resistance, diabetes mellitus, inflammation, metabolic syndrome, obesity
Abstract: Prospective epidemiologic studies have shown that dyslipidemia and hyperglycemia are major risk factors for atherosclerotic cardiovascular diseases. Undesirable metabolic conditions are observed to coexist in patients with metabolic syndrome, which is an important risk factor for cardiovascular disease. To prevent cardiovascular disease, a pleiotropic agent is needed to improve the metabolic disorder in patients with metabolic syndrome. Bile acid binding resins increase the fecal excretion of bile acids. The decrease in bile acids returned to the liver leads to an up-regulation of hepatic low-density lipoprotein (LDL) receptor activity, which decreases LDL cholesterol (LDL-C) in the circulation and increases high-density lipoprotein cholesterol. On the other hand, bile acids can also regulate the transcription of genes involved in LDL-C synthesis and cholesterol homeostasis via nuclear hormone receptors. Consequently, these receptors may represent novel therapeutic targets for dyslipidemia and provide insight into the role of the bile acid pathway in other metabolic processes. This review focuses on the recent findings on bile acid binding resins and cardiovascular disease risk factors. Moreover, known and proposed mechanisms of how bile acid binding resins may improve glucose and energy metabolism are discussed; these effects may help to explain the mechanisms by which bile acid binding resins may reduce cardiovascular disease.
Export Options
About this article
Cite this article as:
Yamaoka-Tojo Minako, Tojo Taiki and Izumi Tohru, Beyond Cholesterol Lowering: Pleiotropic Effects of Bile Acid Binding Resins Against Cardiovascular Disease Risk Factors in Patients with Metabolic Syndrome, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909698
DOI https://dx.doi.org/10.2174/157016108785909698 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-infective Agents Produced by the Hyphomycetes Genera Trichoderma and Gliocladium
Current Medicinal Chemistry - Anti-Infective Agents Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry Mediterranean Diet And Longevity: An Example Of Nutraceuticals?
Current Vascular Pharmacology Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Regulation by Antioxidant Compounds: New Therapeutic Tools for Hypercholesterolemia?
Current Molecular Medicine Coumarine Analogues with Antimycobacterial and Immunomodulatory Activity
Current Bioactive Compounds Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Relationship between Diabetes Mellitus and Coronary Heart Disease
Current Diabetes Reviews Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design